Ebola Vaccine Appeared Effective
VSV-EBOV Ebola vaccine, from GlaxoSmithKline, appeared effective in fight against Ebola
The VSV-EBOV vaccine is a bright spot in the fight against Ebola. Early tests of the experimental Ebola vaccine found it to be highly effective, according to the World Health Organization (WHO).
Studies on this vaccine, which only requires one dose, began in March of 2015 in Guinea, where Ebola ravaged the country in one of the largest Ebola outbreaks in history.
Based on these trials, WHO officials said they planned to deploy the vaccine immediately to at-risk groups, reported CNN.
Over 4,000 at-risk patients voluntarily participated in the WHO trial, as well as over 1,200 health workers.
The results suggested that the vaccine was 100 percent effective.
The trial results were published in The Lancet.
Funding came from WHO, the Wellcome Trust, Médecins Sans Frontières, the Norwegian Ministry of Foreign Affairs and the Canadian government.
Researchers disclosed financial ties to GlaxoSmithKline, which developed the vaccine, and WHO.
- The Centers for Disease Control and Prevention, "2014 Ebola Outbreak in West Africa
- CNN, "WHO: Trials show new Ebola vaccine is 'highly effective'"
- The Lancet, "Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results f..."
- World Health Organization, "World on the verge of an effective Ebola vaccine"